Just in case anyone wishes to understand the risks associated...

Just in case anyone wishes to understand the risks associated with the upcoming 008 readout! GLATH

"PARA_OA_008 Clinical Trial: The PARA_OA_008 Phase 2 clinical trial aims to provide evidence that disease specific biomarkers in the synovial fluid of symptomatic OA patients are a potential marker of Zilosul® effects on the joint.Osteoarthritis is a chronic progressive disease of the whole joint, with pre-clinical and clinical evidence has demonstrated that PPS is active through multiple modes of action including decreasing inflammation by down-regulatinginflammatory cytokines, reducing pain by reducing the production of NGF, protecting cartilage as evidenced by the downregulation of cartilage degrading enzymes, and supporting bone repair through improved blood flow. Previously,these effects have been evaluated by measuring serum biomarkers which may not fully describe the changes in the local OA joint environment. Whilst Paradigm’s prior Phase 2B (PARA_OA_005) clinical trial did show a decrease inserum biomarkers in PPS patients compared with placebo, investors should note there is no guarantee that results will be replicated within the synovial fluid in the current PARA_OA_008 Phase 2 clinical trial, nor that regulatoryauthorities will find the data generated from this trial as sufficient to support Paradigm moving to a Phase 3 trial in Osteoarthritis. It is anticipated that patient recruitment, treatment and accordingly the results of Paradigm’s Phase 2BPARA_OA_008 clinical trial may read out in the near term. This could be an important value inflexion for Paradigm in reviewing its disease modifying potential for PPS in Osteoarthritis"